Inflammation in Melasma: Study of Its Infiltrate and the Expression of Acute and Chronic Mediators
Study Details
Study Description
Brief Summary
Melasma is an acquired hyperpigmentary disorder that commonly affects women from Asia and Latin-America.There is evidence of subclinical inflammation supported by diffuse spectrometry and by prominent inflammatory cells in affected areas; however this infiltrate and its inflammatory mediators remains unexplored. Chronic inflammation induces melanogenesis and angiogenesis; thus, it could be linked to its recurrent nature.Therefore, the aim of this study is to describe the inflammatory cellular infiltrate, and the expression of main inflammatory and angiogenic mediators in this condition, as well as to explore its relationship with severity of disease.
Using histological, histochemistry, immunohistochemistry, and quantitative real-time PCR, we evaluated melasma lesions from 20 healthy female patients with malar melasma without specific solar exposure or photoprotection measures within the previous 3 weeks and compared them to non lesional skin.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
Melasma is a frequent, photoinduced, pigmentary disorder among latin-american women. Its etiology is not completely elucidated; however, there is evidence of a melanogenic paracrine cytokine network between the melanocyte and other skin cells, including keratinocytes, fibroblasts, vascular and inflammatory cells, which regulate melanocyte function.
Previous reports in lesional skin have described increased mast cell infiltration in elastotic areas, presence of a moderate lymphohistiocytic infiltrate, increased vascularity, and up-regulation of proangiogenic factors. This histological evidence of skin inflammation is also supported clinically by colorimetry and thermography, and by the improvement of pigmentation with topical anti-inflammatories.
Photoinduced dermal inflammation might be related to epidermal hyperpigmentation through the production of melanogenic cytokines, and growth factors, and through the secretion of COX-2 induced prostaglandins by keratinocytes, a mechanism involved in the pathogenesis of postinflammatory hyperpigmentation which has not been evaluated in melasma.
The aim of this study is to describe the ongoing characteristics of inflammation in this condition by measuring the cellular infiltrate, the expression of acute and chronic immune inflammatory mediators, and non-immune inflammation mechanism such as COX-2, as well as to explore its relationship with severity of disease, elastosis, and melanin staining.
Twenty healthy female patients with malar melasma without specific solar exposure or photoprotection measures within the previous 3 weeks were enrolled. Disease severity was estimated using the Melasma Area and Severity Index (MASI). Histological, histochemical, immunohistochemistry, and quantitative real-time PCR were used to evaluate the presence of these markers in melasma lesions and compare them to nonlesional skin.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Melasma Women affected by symmetric facial malar melasma. |
Outcome Measures
Primary Outcome Measures
- Inflammatory cellular infiltrate [Single time measurement]
Determine by immunohistochemistry common inflammatory cellular infiltrate in melasma lesions and non affected skin (i.e CD1, CD68, CD4, CD8).
Secondary Outcome Measures
- Acute inflammatory mediators [Single time measurement]
Determine by immunohistochemistry, and PCR techniques, the expression of IL1 alpha, IL1 beta, IL1 alpha receptor, and VEGF in melasma lesions and non affected skin.
- Chronic inflammatory mediators [Single time measurement]
Determine by immunohistochemistry, and PCR techniques, the expression of COX-2, and IL-17 in melasma lesions and non affected skin.
Other Outcome Measures
- Correlation between inflammation markers and pigmentation [Single time measurement]
Analyze inflammation parameters and to correlate data with melanin, elastosis, and clinical parameters of severity.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Women older than 18 years under signed informed consent form.
-
Symmetrical and bilateral lesions.
-
Melasma with MASI scores greater than 12 points.
Exclusion Criteria:
-
Melasma treatment or photoprotection measures within last 2 months.
-
Pregnant women or nursing.
-
Miscarriage or labor in the last 12 months.
-
Menopause
-
Coexistence of other pigmentation disorders.
-
Infrared radiation exposure.
-
Regular exercise or diet restriction.
-
Consumption of food supplements.
-
Any type of drugs consumption in the last 2 months (i.e anti-inflammatories and hormonal treatments)
-
Personal history of keloid or hypertrophic scars.
-
Lidocaine allergy.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Hospital Central Dr. Ignacio Morones Prieto | San Luis Potosi | Mexico | 78210 |
Sponsors and Collaborators
- Universidad Autonoma de San Luis Potosí
- Hospital Central "Dr. Ignacio Morones Prieto"
Investigators
- Study Director: Juan P Castanedo-Cazares, MD, Hospital Central "Dr. Ignacio Morones Prieto"
- Study Chair: Bertha Torres-Alvarez, MD, Hospital Central "Dr. Ignacio Morones Prieto"
- Principal Investigator: Adriana Rodriguez-Arambula, MD, Hospital Central "Dr. Ignacio Morones Prieto"
Study Documents (Full-Text)
None provided.More Information
Publications
- Espinal-Perez LE, Moncada B, Castanedo-Cazares JP. A double-blind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma. Int J Dermatol. 2004 Aug;43(8):604-7.
- Hernández-Barrera R, Torres-Alvarez B, Castanedo-Cazares JP, Oros-Ovalle C, Moncada B. Solar elastosis and presence of mast cells as key features in the pathogenesis of melasma. Clin Exp Dermatol. 2008 May;33(3):305-8. doi: 10.1111/j.1365-2230.2008.02724.x.
- Moncada B, Sahagún-Sánchez LK, Torres-Alvarez B, Castanedo-Cázares JP, Martínez-Ramírez JD, González FJ. Molecular structure and concentration of melanin in the stratum corneum of patients with melasma. Photodermatol Photoimmunol Photomed. 2009 Jun;25(3):159-60. doi: 10.1111/j.1600-0781.2009.00425.x.
- Navarrete-Solís J, Castanedo-Cázares JP, Torres-Álvarez B, Oros-Ovalle C, Fuentes-Ahumada C, González FJ, Martínez-Ramírez JD, Moncada B. A Double-Blind, Randomized Clinical Trial of Niacinamide 4% versus Hydroquinone 4% in the Treatment of Melasma. Dermatol Res Pract. 2011;2011:379173. doi: 10.1155/2011/379173. Epub 2011 Jul 21.
- Torres-Álvarez B, Mesa-Garza IG, Castanedo-Cázares JP, Fuentes-Ahumada C, Oros-Ovalle C, Navarrete-Solis J, Moncada B. Histochemical and immunohistochemical study in melasma: evidence of damage in the basal membrane. Am J Dermatopathol. 2011 May;33(3):291-5. doi: 10.1097/DAD.0b013e3181ef2d45.
- mel-Infla1